Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (33)

2024

  1. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 10-15

  2. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  3. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

2023

  1. Consensus about monoclonal antibodies in migraine of the Headache Study Group of the Madrid Association of Neurology

    Kranion, Vol. 18, Núm. 1, pp. 5-20

  2. Development and Performance Evaluation of a Clinical Predictive Model to Estimate the Risk of Red Blood Cell Requirements in Brain Tumor Surgery

    Journal of Neurosurgical Anesthesiology, Vol. 35, Núm. 1, pp. 74-79

2022

  1. Preoperative Hemoglobin and Actual Need for Blood Transfusion in Brain Tumor Resection Procedures: A Retrospective Cohort Study

    Journal of Neurosurgical Anesthesiology

2021

  1. 1st Post-European Headache Federation Meeting: A review of the latest developments presented at the 2020 European Headache Federation Congress

    Revista de Neurologia

  2. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

    Neurology, Vol. 97, Núm. 14, pp. E1367-E1381

  3. Present and future of parkinson’s disease in Spain: Parkinson-2030 delphi project

    Brain Sciences, Vol. 11, Núm. 8

2020

  1. Primary central nervous system lymphoma and 5-aminolevulinic acid

    Surgical Neurology International, Vol. 11, Núm. 122

  2. Vestibular impairment in hemifacial spasm syndrome: A case report

    Journal of International Advanced Otology, Vol. 16, Núm. 1, pp. 138-140

2018

  1. Mitos y evidencias en el empleo de la toxina botulínica: Neurofarmacología y distonías

    Revista de Neurologia, Vol. 66, Núm. 5, pp. 163-172

  2. Phenomenology and disease progression of chorea-acanthocytosis patients in Spain

    Parkinsonism and Related Disorders, Vol. 49, pp. 17-21

  3. Treatable inherited rare movement disorders

    Movement Disorders, Vol. 33, Núm. 1, pp. 21-35

  4. «Apuntes en Neurologia»: una sintesis de la evidencia en trastornos neurologicos comunes paroxisticos y en trastornos neurodegenerativos

    Revista de neurologia, Vol. 67, Núm. s01, pp. S1-S21

2017

  1. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study

    Epilepsy and Behavior, Vol. 73, pp. 173-179

  2. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series

    Seizure, Vol. 48, pp. 53-56

  3. Enhanced Missing Proteins Detection in NCI60 Cell Lines Using an Integrative Search Engine Approach

    Journal of Proteome Research, Vol. 16, Núm. 12, pp. 4374-4390

2014

  1. Agonistas dopaminérgicos en la enfermedad de Parkinson

    Neurologia

2013

  1. Advanced Parkinson's disease: Clinical characteristics and treatment (part 1)

    Neurologia, Vol. 28, Núm. 8, pp. 503-521